PCSK9 inhibitors decrease LDL-C by 50–60% from the baseline, lower cardiovascular disease risk similar to statins, and demonstrate strong additive effect when administered in combination with statins [66,67,68]. This evidence concerns the gene PCSK9 and cardiovascular disorder.